Pharming Group NV (Pharming) develops precision medicines and innovative protein replacement therapies for the treatment of rare diseases and unmet medical needs. The company’s marketed product includes, Ruconest (conestat alfa), a recombinant human C1 inhibitor is used for the treatment of acute hereditary angioedema (HAE) and has been approved in the US, the UK, Europe, Israel, and South Korea. Its product pipeline consists of rhC1INH for the treatment of pre-eclampsia, COVID-19 and acute kidney injury; leniolisib for treatment of activated phosphoinositide 3-kinase delta syndrome (APDS); α-Glucosidase for the treatment of pompe and fabry’s disease. The company markets its products through own sales force and network of distributors and partners. Pharming is headquartered in Leiden, the Netherlands.
Headquarters
Netherlands
Address
Darwinweg 24, Leiden, 2333CR
Website
www.pharming.com
Telephone
31 71 5247400
No of Employees
321
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PHARM (AMS)
Revenue (2021)
$198.9M
-9.7%
(2021 vs 2020)
EPS
XXX
Net Income (2021)
XXX
-59.2%
(2021 vs 2020)
Market Cap*
$528.5M
Net Profit Margin (2021)
XXX
-54.8%
(2021 vs 2020)
* As of and is in US$
Explore premium data & analytics
Products and Services
| Products | Brands |
|---|---|
| Ruconest- Acute Hereditary Angioedema (HAE) | Ruconest |
| Pipeline | |
| rhC1INH- Pre-Eclampsia, COVID-19 and Acute Kidney Injury | |
| XXX | |
| XXX | |
| XXX |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2021 | Contracts/Agreements | In December, the company renewed its manufacturing partnership with Sanofi SA. |
| 2021 | Contracts/Agreements | In July, the company and NewBridge Pharmaceuticals signed a licence agreement for the distribution of RUCONEST in the Middle East and North Africa. |
| 2021 | Contracts/Agreements | In July, the company entered into a strategic collaboration with Orchard Therapeutics to research, develop, manufacture and commercialize OTL-105 for the treatment of hereditary angioedema. |
Competitor Comparison
| Key Parameters | Pharming Group NV | Galapagos NV | Argenx SE | Lannett Co Inc | Crucell NV (Inactive) |
|---|---|---|---|---|---|
| Headquarters | Netherlands | Belgium | Netherlands | United States of America | Netherlands |
| City | Leiden | Malines (Mechelen) | Breda | Trevose | Leiden |
| State/Province | - | - | - | Pennsylvania | Zuid-Holland |
| No. of Employees | 321 | 1,305 | 650 | 812 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Operating Margin
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paul Sekhri | Chairman | Executive Board | 2008 | 63 |
| Sijmen De Vries, M.D. | Director; Chief Executive Officer | Executive Board | 2016 | 61 |
| Jeroen Wakkerman | Chief Financial Officer | Senior Management | 2020 | 51 |
| Mireille Sanders | Chief Operating Officer | Senior Management | 2020 | 53 |
| Anurag Relan | Chief Medical Officer | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
| Non Dignissim Eros | Proin vel | Convallis | 2022 | XX |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer